Form 4: Zentalis Pharmaceuticals Director Acquires Stock

David Michael Johnson, a Director at Zentalis Pharmaceuticals, Inc., acquired 57,100 shares of common stock through a grant of restricted stock units.

Summary

• David Michael Johnson, a Director of Zentalis Pharmaceuticals, Inc., was granted 57,100 restricted stock units (RSUs) on June 16, 2026.
• These RSUs represent a contingent right to receive one share of common stock per unit.
• The RSUs are set to vest on the earlier of June 16, 2027, or the next annual meeting of stockholders, provided Mr. Johnson continues to serve on the Board of Directors.
• Following this transaction, Mr. Johnson beneficially owns 307,521 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation grant to a director rather than a significant financial event or strategic shift.

Positives

• Director David Michael Johnson's acquisition of restricted stock units indicates continued commitment and alignment with the company's performance.
• The grant of 57,100 RSUs demonstrates a form of long-term incentive compensation for a key board member.

Future Outlook

The restricted stock units granted to David Michael Johnson will vest on the earlier of June 16, 2027, or the next annual meeting of stockholders, contingent upon his continued service on the Board of Directors.

Industry Context

StockSavvy.ai notes that the issuance of restricted stock units to directors is a common practice in the biopharmaceutical industry to align executive and board compensation with long-term shareholder value and company performance.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns director incentives with long-term shareholder value, though it represents a dilution of ownership upon vesting.
• Employees: This filing does not directly impact employees but reflects standard compensation practices for board members.
• Management: The filing confirms a standard compensation practice for directors.

Next Steps

• David Michael Johnson to continue service on the Board of Directors through the vesting date.
• Vesting of 57,100 restricted stock units on or before June 16, 2027, or the next annual meeting.

Key Dates

Keywords

Zentalis Pharmaceuticals, Form 4, SEC Filing, Director Compensation, Restricted Stock Units, Equity Grant, Beneficial Ownership, Stock Vesting